Effect of glucagon-like peptide-2 exposure on bone resorption: Effectiveness of high concentration versus prolonged exposure

Regulatory Peptides

Volumn 181, Issue 1, 2013, Pages 4-8

  Askov Hansen, Carsten ^a   Jeppesen, Palle B ^a   Lund, Pernille ^a   Hartmann, Bolette ^b   Holst, Jens J ^b   Henriksen, Dennis B ^c  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Sanos Bioscience   (Denmark)

Author keywords

Bone remodeling; GLP 2; P CTX

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; GLUCAGON LIKE PEPTIDE 2; SITAGLIPTIN;

ADULT; ARTICLE; CHRONIC DRUG ADMINISTRATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AREA UNDER CURVE; BIOLOGICAL MARKERS; BONE RESORPTION; COLLAGEN TYPE I; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCAGON-LIKE PEPTIDE 2; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PYRAZINES; TRIAZOLES;

EID: 84872466358     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2012.11.002     Document Type: Article

References (17)

1. Parfitt A.M. Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 1994, 55(3):273-286.
2. Christgau S., Bitsch-Jensen O., Hanover B.N., et al. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 2000, 26(5):505-511.
3. Quist P., Christgau S., Pedersen B.J., et al. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTX): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 2002, 31(1):57-61.
4. Hannon R.A., Yap T.S., Hoyle N.R., Blumsohn A., Eastell R. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone Jun 2002, 30(6):886-890.
5. Henriksen D.B., Alexandersen P., Bjarnason N.H., et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 2003, 18(12):2180-2189.
6. Hartmann B., Johnsen A.H., Orskov C., et al. Structure, measurement, and secretion of human glucagon-like peptide-2. Peptides 2000, 21(1):73-80.
7. Brubaker P.L., Crivici A., Izzo A., et al. Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide-2. Endocrinology 1997, 138(11):4837-4843.
8. Xiao Q., Boushey R.P., Drucker D.J., Brubaker P.L. Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans. Gastroenterology 1999, 177:99-105.
9. Henriksen D.B., Alexandersen P., Hartmann B., Adrian C.L., Byrjalsen I., Bone H.G., Holst J.J., Christiansen C. Disassociation of bone resorption and formation by GLP-2. A 14-day study in healthy postmenopausal women. Bone 2007, 40:723-729.
10. Hartmann B., Harr M.B., Jeppesen P.B., et al. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab Aug 2000, 85(8):2884-2888.
11. Jeppesen P.B., Sanguinetti E.L., Buchman A., et al. Teduglutide (ALX-0600), a dipeptidyl peptidase 4 resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 2005, 54:1224-1231.
12. Hartmann B., Thulesen J., Kissow H., et al. Dipeptidyl peptidase 4 inhibition enhances the intestinotrophic effect of glucagon-like peptide 2 in rats and mice. Endocrinology 2000, 141:4013-4020.
13. Martin G.R., Wallace L.E., Hartmann B., et al. Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2005, 288:G431-G438.
14. Henriksen D.B., Alexandersen P., Byrjalsen I., et al. Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. Bone 2004, 34:140-147.
15. Gottschalck I.B., et al. Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomi and short-bowel syndrome. Scand J Gastroenterol 2008, 43(11):1304-1310.
16. Jeppesen P.B., et al. Elevated plasma glucagon-like peptide-1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut Sep 2000, 47(3):370-376.
17. Henriksen D.B., et al. Four-month treatment with glucagon-like peptide-2 significantly increases hip BMD: a randomized placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone Nov 2009, 45(5):833-842. [Epub 2009 jul 22].